WRAGGE & Co’s Corporate group has advised new client Bioline group on its US $23.3 million (£15.2 million) cross-border acquisition by NASDAQ-listed Meridian Bioscience Inc.
Corporate partner Kevin Jones led a cross-firm team advising the shareholders of Bioline, a leading global manufacturer and distributor of molecular biology reagents to the research market with operations in the UK, US, Germany and Australia. The deal represents a strategic acquisition for Cincinnati-based Meridian Bioscience Inc, as it looks to increase its activity in the specialist reagent market.
Marco Calzavara, founder and CEO of Bioline, said: “Kevin and the team at Wragge & Co provided exemplary legal support which enabled us to conclude the sale of Bioline within an aggressive time schedule, but without compromising the agreement. We received exactly the right blend of legal advice and commercial pragmatism that we needed.”
Kevin Jones added: “This was a complex, cross-border transaction, which involved coordinating various parties in different jurisdictions. Our wide-ranging M&A experience, life sciences expertise and our commercial, sector-focused approach ensured we achieved a successful outcome within a challenging timescale.”
Corporate associate Chris Towle, solicitor Amar Adatia, life sciences partner Pat Duxbury and employment specialist Chloe Lawton also supported. The team worked with US-based Cooley Godward Kronish to ensure compliance with Delaware law, Australia-based Blake Dawson and Germany-based Uwe Rößler. Keating
Muething & Klekamp advised Meridian Bioscience Inc.
If you are interested in working in partnership with TheBusinessDesk.com on a round table event, call Lee-J Walker on 07890 045878 or email him here leej.walker@TheBusinessDesk.com
Click here to sign up to receive our new South West business news...
